ID HECD1_HUMAN Reviewed; 2610 AA. AC Q9ULT8; D3DS86; Q6P445; Q86VJ1; Q96F34; Q9UFZ7; DT 12-FEB-2003, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 4. DT 27-MAR-2024, entry version 201. DE RecName: Full=E3 ubiquitin-protein ligase HECTD1 {ECO:0000305}; DE EC=2.3.2.26 {ECO:0000269|PubMed:33711283}; DE AltName: Full=E3 ligase for inhibin receptor; DE Short=EULIR {ECO:0000303|Ref.1}; DE AltName: Full=HECT domain-containing protein 1; GN Name=HECTD1 {ECO:0000303|PubMed:33711283, GN ECO:0000312|HGNC:HGNC:20157}; Synonyms=KIAA1131; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-2027. RA Zhang H.; RT "EULIR is an E3 ubiquitin ligase for inhibin receptor."; RL Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 443-2610. RC TISSUE=Brain; RX PubMed=10574461; DOI=10.1093/dnares/6.5.329; RA Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.; RT "Characterization of cDNA clones selected by the GeneMark analysis from RT size-fractionated cDNA libraries from human brain."; RL DNA Res. 6:329-336(1999). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1652-2610. RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2091-2610. RC TISSUE=Muscle, and Urinary bladder; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP INTERACTION WITH IGSF1. RX PubMed=12421765; DOI=10.1101/gr.406902; RA Nakayama M., Kikuno R., Ohara O.; RT "Protein-protein interactions between large proteins: two-hybrid screening RT using a functionally classified library composed of long cDNAs."; RL Genome Res. 12:1773-1784(2002). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1488, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1760 AND SER-1772, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2318, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF CYS-2579. RX PubMed=33711283; DOI=10.1016/j.stem.2021.02.008; RA Lv K., Gong C., Antony C., Han X., Ren J.G., Donaghy R., Cheng Y., RA Pellegrino S., Warren A.J., Paralkar V.R., Tong W.; RT "HectD1 controls hematopoietic stem cell regeneration by coordinating RT ribosome assembly and protein synthesis."; RL Cell Stem Cell 28:1275-1290(2021). RN [16] RP STRUCTURE BY NMR OF 1266-1338. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of MIB-HERC2 domain in HECT domain containing protein RT 1."; RL Submitted (OCT-2006) to the PDB data bank. CC -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from an CC E2 ubiquitin-conjugating enzyme in the form of a thioester and then CC directly transfers the ubiquitin to targeted substrates CC (PubMed:33711283). Mediates 'Lys-63'-linked polyubiquitination of CC HSP90AA1 which leads to its intracellular localization and reduced CC secretion (By similarity). Negatively regulating HSP90AA1 secretion in CC cranial mesenchyme cells may impair their emigration and may be CC essential for the correct development of the cranial neural folds and CC neural tube closure (By similarity). Catalyzes ubiquitination and CC degradation of ZNF622, an assembly factor for the ribosomal 60S CC subunit, in hematopoietic cells, thereby promoting hematopoietic stem CC cell renewal (PubMed:33711283). {ECO:0000250|UniProtKB:Q69ZR2, CC ECO:0000269|PubMed:33711283}. CC -!- CATALYTIC ACTIVITY: CC Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine + CC [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L- CC cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.; CC EC=2.3.2.26; Evidence={ECO:0000269|PubMed:33711283}; CC -!- PATHWAY: Protein modification; protein ubiquitination. CC {ECO:0000269|PubMed:33711283}. CC -!- SUBUNIT: Interacts with IGSF1 (PubMed:12421765). CC {ECO:0000269|PubMed:12421765}. CC -!- SIMILARITY: Belongs to the UPL family. K-HECT subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AY254380; AAP13073.1; -; mRNA. DR EMBL; AL121808; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL136418; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471078; EAW65950.1; -; Genomic_DNA. DR EMBL; CH471078; EAW65952.1; -; Genomic_DNA. DR EMBL; AB032957; BAA86445.2; -; mRNA. DR EMBL; AL110222; CAB53681.1; -; mRNA. DR EMBL; BC011658; AAH11658.2; -; mRNA. DR EMBL; BC063686; AAH63686.1; -; mRNA. DR CCDS; CCDS41939.1; -. DR PIR; T14761; T14761. DR RefSeq; NP_056197.3; NM_015382.3. DR RefSeq; XP_005267559.2; XM_005267502.2. DR PDB; 2DK3; NMR; -; A=1266-1338. DR PDB; 2LC3; NMR; -; A=1879-1966. DR PDB; 3DKM; X-ray; 1.60 A; A=1271-1341. DR PDBsum; 2DK3; -. DR PDBsum; 2LC3; -. DR PDBsum; 3DKM; -. DR AlphaFoldDB; Q9ULT8; -. DR BMRB; Q9ULT8; -. DR SMR; Q9ULT8; -. DR BioGRID; 117359; 405. DR DIP; DIP-31669N; -. DR IntAct; Q9ULT8; 54. DR MINT; Q9ULT8; -. DR STRING; 9606.ENSP00000382269; -. DR GlyCosmos; Q9ULT8; 12 sites, 2 glycans. DR GlyGen; Q9ULT8; 21 sites, 2 O-linked glycans (21 sites). DR iPTMnet; Q9ULT8; -. DR PhosphoSitePlus; Q9ULT8; -. DR SwissPalm; Q9ULT8; -. DR BioMuta; HECTD1; -. DR DMDM; 313104227; -. DR EPD; Q9ULT8; -. DR jPOST; Q9ULT8; -. DR MassIVE; Q9ULT8; -. DR MaxQB; Q9ULT8; -. DR PaxDb; 9606-ENSP00000382269; -. DR PeptideAtlas; Q9ULT8; -. DR ProteomicsDB; 85108; -. DR Pumba; Q9ULT8; -. DR Antibodypedia; 5457; 144 antibodies from 25 providers. DR DNASU; 25831; -. DR Ensembl; ENST00000399332.6; ENSP00000382269.1; ENSG00000092148.14. DR Ensembl; ENST00000553700.5; ENSP00000450697.1; ENSG00000092148.14. DR GeneID; 25831; -. DR KEGG; hsa:25831; -. DR MANE-Select; ENST00000399332.6; ENSP00000382269.1; NM_015382.4; NP_056197.3. DR UCSC; uc001wrc.1; human. DR AGR; HGNC:20157; -. DR CTD; 25831; -. DR DisGeNET; 25831; -. DR GeneCards; HECTD1; -. DR HGNC; HGNC:20157; HECTD1. DR HPA; ENSG00000092148; Tissue enhanced (skeletal). DR MIM; 618649; gene. DR neXtProt; NX_Q9ULT8; -. DR OpenTargets; ENSG00000092148; -. DR PharmGKB; PA134989284; -. DR VEuPathDB; HostDB:ENSG00000092148; -. DR eggNOG; KOG4276; Eukaryota. DR GeneTree; ENSGT00940000156572; -. DR HOGENOM; CLU_000869_0_0_1; -. DR InParanoid; Q9ULT8; -. DR OMA; INHTLTM; -. DR OrthoDB; 1093891at2759; -. DR PhylomeDB; Q9ULT8; -. DR TreeFam; TF323674; -. DR PathwayCommons; Q9ULT8; -. DR Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation. DR SignaLink; Q9ULT8; -. DR SIGNOR; Q9ULT8; -. DR UniPathway; UPA00143; -. DR BioGRID-ORCS; 25831; 305 hits in 1213 CRISPR screens. DR ChiTaRS; HECTD1; human. DR EvolutionaryTrace; Q9ULT8; -. DR GenomeRNAi; 25831; -. DR Pharos; Q9ULT8; Tbio. DR PRO; PR:Q9ULT8; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q9ULT8; Protein. DR Bgee; ENSG00000092148; Expressed in tibialis anterior and 176 other cell types or tissues. DR ExpressionAtlas; Q9ULT8; baseline and differential. DR GO; GO:0016607; C:nuclear speck; IBA:GO_Central. DR GO; GO:0046872; F:metal ion binding; IEA:InterPro. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB. DR GO; GO:0048856; P:anatomical structure development; IBA:GO_Central. DR GO; GO:0035904; P:aorta development; ISS:BHF-UCL. DR GO; GO:0003170; P:heart valve development; ISS:BHF-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:FlyBase. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IBA:GO_Central. DR GO; GO:0070534; P:protein K63-linked ubiquitination; IBA:GO_Central. DR GO; GO:0003281; P:ventricular septum development; ISS:BHF-UCL. DR CDD; cd21062; BTHB_HectD1; 1. DR CDD; cd00078; HECTc; 1. DR Gene3D; 1.10.720.80; -; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 3.30.2160.10; Hect, E3 ligase catalytic domain; 1. DR Gene3D; 3.30.2410.10; Hect, E3 ligase catalytic domain; 1. DR Gene3D; 3.90.1750.10; Hect, E3 ligase catalytic domains; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1. DR Gene3D; 2.30.30.40; SH3 Domains; 1. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR041200; FKBP3_BTHB. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR000569; HECT_dom. DR InterPro; IPR035983; Hect_E3_ubiquitin_ligase. DR InterPro; IPR045322; HECTD1/TRIP12-like. DR InterPro; IPR010606; Mib_Herc2. DR InterPro; IPR037252; Mib_Herc2_sf. DR InterPro; IPR012919; SUN_dom. DR PANTHER; PTHR45670:SF19; E3 UBIQUITIN-PROTEIN LIGASE HECTD1; 1. DR PANTHER; PTHR45670; E3 UBIQUITIN-PROTEIN LIGASE TRIP12; 1. DR Pfam; PF12796; Ank_2; 1. DR Pfam; PF18410; BTHB; 1. DR Pfam; PF00632; HECT; 1. DR Pfam; PF06701; MIB_HERC2; 1. DR Pfam; PF07738; Sad1_UNC; 1. DR SMART; SM00248; ANK; 3. DR SMART; SM00119; HECTc; 1. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56204; Hect, E3 ligase catalytic domain; 1. DR SUPFAM; SSF159034; Mib/herc2 domain-like; 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. DR PROSITE; PS50088; ANK_REPEAT; 2. DR PROSITE; PS50237; HECT; 1. DR PROSITE; PS51416; MIB_HERC2; 1. DR Genevisible; Q9ULT8; HS. PE 1: Evidence at protein level; KW 3D-structure; ANK repeat; Phosphoprotein; Reference proteome; Repeat; KW Transferase; Ubl conjugation pathway. FT CHAIN 1..2610 FT /note="E3 ubiquitin-protein ligase HECTD1" FT /id="PRO_0000083945" FT REPEAT 395..424 FT /note="ANK 1" FT REPEAT 426..455 FT /note="ANK 2" FT REPEAT 459..491 FT /note="ANK 3" FT REPEAT 579..612 FT /note="ANK 4" FT DOMAIN 1266..1338 FT /note="MIB/HERC2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00749" FT DOMAIN 2151..2610 FT /note="HECT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00104" FT REGION 246..269 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 489..513 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 627..657 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 707..748 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1343..1406 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1433..1483 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1496..1515 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1592..1611 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1674..1757 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1777..1797 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2029..2103 FT /note="K-box" FT REGION 2297..2318 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 252..269 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 489..512 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 733..748 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1345..1401 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1433..1457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1675..1700 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1701..1721 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1743..1757 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 2579 FT /note="Glycyl thioester intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00104" FT MOD_RES 631 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 640 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q69ZR2" FT MOD_RES 1384 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q69ZR2" FT MOD_RES 1488 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 1567 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q69ZR2" FT MOD_RES 1760 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1772 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2318 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT VARIANT 656 FT /note="Q -> H (in dbSNP:rs11620816)" FT /id="VAR_059666" FT VARIANT 2027 FT /note="P -> L (in dbSNP:rs1315794)" FT /evidence="ECO:0000269|Ref.1" FT /id="VAR_067707" FT MUTAGEN 2579 FT /note="C->G: Abolished E3 ubiquitin-protein ligase FT activity." FT /evidence="ECO:0000269|PubMed:33711283" FT CONFLICT 561 FT /note="K -> Q (in Ref. 1; AAP13073)" FT /evidence="ECO:0000305" FT CONFLICT 603 FT /note="L -> I (in Ref. 1; AAP13073)" FT /evidence="ECO:0000305" FT CONFLICT 611..613 FT /note="FLD -> YKH (in Ref. 1; AAP13073)" FT /evidence="ECO:0000305" FT CONFLICT 653 FT /note="K -> Q (in Ref. 1; AAP13073)" FT /evidence="ECO:0000305" FT CONFLICT 894 FT /note="E -> K (in Ref. 1; AAP13073)" FT /evidence="ECO:0000305" FT CONFLICT 927..944 FT /note="SMDLDMKQDCSQLVERIN -> VSIFRATKQKQNEVPKVILS (in Ref. FT 1; AAP13073)" FT /evidence="ECO:0000305" FT CONFLICT 951 FT /note="S -> T (in Ref. 1; AAP13073)" FT /evidence="ECO:0000305" FT CONFLICT 1281 FT /note="I -> T (in Ref. 2; BAA86445)" FT /evidence="ECO:0000305" FT HELIX 1270..1272 FT /evidence="ECO:0007829|PDB:2DK3" FT STRAND 1279..1282 FT /evidence="ECO:0007829|PDB:3DKM" FT TURN 1289..1292 FT /evidence="ECO:0007829|PDB:3DKM" FT STRAND 1299..1301 FT /evidence="ECO:0007829|PDB:3DKM" FT STRAND 1309..1314 FT /evidence="ECO:0007829|PDB:3DKM" FT TURN 1315..1317 FT /evidence="ECO:0007829|PDB:2DK3" FT STRAND 1319..1325 FT /evidence="ECO:0007829|PDB:3DKM" FT HELIX 1326..1328 FT /evidence="ECO:0007829|PDB:3DKM" FT STRAND 1332..1334 FT /evidence="ECO:0007829|PDB:3DKM" FT HELIX 1883..1886 FT /evidence="ECO:0007829|PDB:2LC3" FT HELIX 1896..1902 FT /evidence="ECO:0007829|PDB:2LC3" FT STRAND 1905..1908 FT /evidence="ECO:0007829|PDB:2LC3" FT HELIX 1910..1920 FT /evidence="ECO:0007829|PDB:2LC3" FT HELIX 1923..1928 FT /evidence="ECO:0007829|PDB:2LC3" FT HELIX 1935..1941 FT /evidence="ECO:0007829|PDB:2LC3" FT HELIX 1944..1957 FT /evidence="ECO:0007829|PDB:2LC3" FT TURN 1960..1962 FT /evidence="ECO:0007829|PDB:2LC3" SQ SEQUENCE 2610 AA; 289368 MW; C02FB51A2AABF98B CRC64; MADVDPDTLL EWLQMGQGDE RDMQLIALEQ LCMLLLMSDN VDRCFETCPP RTFLPALCKI FLDESAPDNV LEVTARAITY YLDVSAECTR RIVGVDGAIK ALCNRLVVVE LNNRTSRDLA EQCVKVLELI CTRESGAVFE AGGLNCVLTF IRDSGHLVHK DTLHSAMAVV SRLCGKMEPQ DSSLEICVES LSSLLKHEDH QVSDGALRCF ASLADRFTRR GVDPAPLAKH GLTEELLSRM AAAGGTVSGP SSACKPGRST TGAPSTTADS KLSNQVSTIV SLLSTLCRGS PVVTHDLLRS ELPDSIESAL QGDERCVLDT MRLVDLLLVL LFEGRKALPK SSAGSTGRIP GLRRLDSSGE RSHRQLIDCI RSKDTDALID AIDTGAFEVN FMDDVGQTLL NWASAFGTQE MVEFLCERGA DVNRGQRSSS LHYAACFGRP QVAKTLLRHG ANPDLRDEDG KTPLDKARER GHSEVVAILQ SPGDWMCPVN KGDDKKKKDT NKDEEECNEP KGDPEMAPIY LKRLLPVFAQ TFQQTMLPSI RKASLALIRK MIHFCSEALL KEVCDSDVGH NLPTILVEIT ATVLDQEDDD DGHLLALQII RDLVDKGGDI FLDQLARLGV ISKVSTLAGP SSDDENEEES KPEKEDEPQE DAKELQQGKP YHWRDWSIIR GRDCLYIWSD AAALELSNGS NGWFRFILDG KLATMYSSGS PEGGSDSSES RSEFLEKLQR ARGQVKPSTS SQPILSAPGP TKLTVGNWSL TCLKEGEIAI HNSDGQQATI LKEDLPGFVF ESNRGTKHSF TAETSLGSEF VTGWTGKRGR KLKSKLEKTK QKVRTMARDL YDDHFKAVES MPRGVVVTLR NIATQLESSW ELHTNRQCIE SENTWRDLMK TALENLIVLL KDENTISPYE MCSSGLVQAL LTVLNNSMDL DMKQDCSQLV ERINVFKTAF SENEDDESRP AVALIRKLIA VLESIERLPL HLYDTPGSTY NLQILTRRLR FRLERAPGET ALIDRTGRML KMEPLATVES LEQYLLKMVA KQWYDFDRSS FVFVRKLREG QNFIFRHQHD FDENGIIYWI GTNAKTAYEW VNPAAYGLVV VTSSEGRNLP YGRLEDILSR DNSALNCHSN DDKNAWFAID LGLWVIPSAY TLRHARGYGR SALRNWVFQV SKDGQNWTSL YTHVDDCSLN EPGSTATWPL DPPKDEKQGW RHVRIKQMGK NASGQTHYLS LSGFELYGTV NGVCEDQLGK AAKEAEANLR RQRRLVRSQV LKYMVPGARV IRGLDWKWRD QDGSPQGEGT VTGELHNGWI DVTWDAGGSN SYRMGAEGKF DLKLAPGYDP DTVASPKPVS STVSGTTQSW SSLVKNNCPD KTSAAAGSSS RKGSSSSVCS VASSSDISLG STKTERRSEI VMEHSIVSGA DVHEPIVVLS SAENVPQTEV GSSSSASTST LTAETGSENA ERKLGPDSSV RTPGESSAIS MGIVSVSSPD VSSVSELTNK EAASQRPLSS SASNRLSVSS LLAAGAPMSS SASVPNLSSR ETSSLESFVR RVANIARTNA TNNMNLSRSS SDNNTNTLGR NVMSTATSPL MGAQSFPNLT TPGTTSTVTM STSSVTSSSN VATATTVLSV GQSLSNTLTT SLTSTSSESD TGQEAEYSLY DFLDSCRAST LLAELDDDED LPEPDEEDDE NEDDNQEDQE YEEVMILRRP SLQRRAGSRS DVTHHAVTSQ LPQVPAGAGS RPIGEQEEEE YETKGGRRRT WDDDYVLKRQ FSALVPAFDP RPGRTNVQQT TDLEIPPPGT PHSELLEEVE CTPSPRLALT LKVTGLGTTR EVELPLTNFR STIFYYVQKL LQLSCNGNVK SDKLRRIWEP TYTIMYREMK DSDKEKENGK MGCWSIEHVE QYLGTDELPK NDLITYLQKN ADAAFLRHWK LTGTNKSIRK NRNCSQLIAA YKDFCEHGTK SGLNQGAIST LQSSDILNLT KEQPQAKAGN GQNSCGVEDV LQLLRILYIV ASDPYSRISQ EDGDEQPQFT FPPDEFTSKK ITTKILQQIE EPLALASGAL PDWCEQLTSK CPFLIPFETR QLYFTCTAFG ASRAIVWLQN RREATVERTR TTSSVRRDDP GEFRVGRLKH ERVKVPRGES LMEWAENVMQ IHADRKSVLE VEFLGEEGTG LGPTLEFYAL VAAEFQRTDL GAWLCDDNFP DDESRHVDLG GGLKPPGYYV QRSCGLFTAP FPQDSDELER ITKLFHFLGI FLAKCIQDNR LVDLPISKPF FKLMCMGDIK SNMSKLIYES RGDRDLHCTE SQSEASTEEG HDSLSVGSFE EDSKSEFILD PPKPKPPAWF NGILTWEDFE LVNPHRARFL KEIKDLAIKR RQILSNKGLS EDEKNTKLQE LVLKNPSGSG PPLSIEDLGL NFQFCPSSRI YGFTAVDLKP SGEDEMITMD NAEEYVDLMF DFCMHTGIQK QMEAFRDGFN KVFPMEKLSS FSHEEVQMIL CGNQSPSWAA EDIINYTEPK LGYTRDSPGF LRFVRVLCGM SSDERKAFLQ FTTGCSTLPP GGLANLHPRL TVVRKVDATD ASYPSVNTCV HYLKLPEYSS EEIMRERLLA ATMEKGFHLN //